Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute for Clinical Genetics, |
RCV003237653 | SCV002011422 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002258310 | SCV002527960 | uncertain significance | Fanconi anemia | 2021-07-14 | criteria provided, single submitter | curation | |
Fulgent Genetics, |
RCV001771642 | SCV002815106 | uncertain significance | Fanconi anemia complementation group E | 2024-04-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001771642 | SCV003782102 | uncertain significance | Fanconi anemia complementation group E | 2022-08-03 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 105 of the FANCE protein (p.Val105Ile). This variant is present in population databases (rs373159305, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with FANCE-related conditions. ClinVar contains an entry for this variant (Variation ID: 1319661). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |